Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449055 · ClinicalTrials.gov registry record · NA
Pilot TMS for Methamphetamine Use Disorder
A NA study of Methamphetamine-dependence and Stimulant Dependence, sponsored by Ryan M. Carnahan.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04449055: Completed NA study of Methamphetamine-dependence and Stimulant Dependence, sponsored by Ryan M. Carnahan.
NCT04449055 is a NA study of Methamphetamine-dependence and Stimulant Dependence that has completed, run by Ryan M. Carnahan. The registered enrollment target is 19 participants, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04449055, a NA study of Methamphetamine-dependence and Stimulant Dependence, has completed, sponsored by Ryan M. Carnahan.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to test the feasibility of a recruitment strategy and study protocol to examine the effects of a dual target transcranial magnetic stimulation treatment in methamphetamine use disorder. The study will test intermittent theta burst stimulation (TBS) targeting the dorsolateral prefrontal cortex (DLPFC) combined with continuous TBS targeting the medial prefrontal cortex (MPFC) in people with methamphetamine use disorder (MAUD) who are engaged in psychosocial treatment. We will randomize the order in which these treatments are delivered at each treatment session, but all subjects will receive both treatments. Intermittent TBS targeting the DLPFC is approved by the Food and Drug Administration for major depressive disorder, and continuous TBS targeting the MPFC has been studied in cocaine use disorder. We will administer this dual target TBS daily for 2 weeks, followed by three times weekly for 2 weeks, and monitor depressive symptoms, anxiety, sleep, craving, quality of life, and methamphetamine use for three months. Changes in functional connectivity of brain circuits will be evaluated with functional magnetic resonance imaging (fMRI) before and after treatment. We expect to observe changes in connectivity between the DLPFC, MPFC, and other regions implicated in addiction and impulsivity. Furthermore, we will evaluate if baseline differences in functional connectivity can be used to predict response. Psychological tests focusing on state impulsivity and risk taking will be administered, and we expect to observe reductions in these characteristics after treatment. We will test this protocol in 20 patients recruited from clinical care settings at University of Iowa Hospitals and Clinics, University of New Mexico Health System, and University of Utah Health to illustrate the feasibility of recruitment and completing the protocol, to support an external funding proposal.
Primary Outcome
Time to study dropout (to assess feasibility and tolerability of the protocol)
Conditions Studied
Interventions
- DEVICE Transcranial Magnetic Stimulation--DPFC first, MPFC second
- DEVICE Transcranial Magnetic Stimulation--MPFC first, DPFC second
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
What the finished NCT04449055 record still lists
NCT04449055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 2 interventions - of which Transcranial Magnetic Stimulation--DPFC first, MPFC second is the first listed.
NCT04449055 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT04449055 about?
NCT04449055 is a clinical study titled "Pilot TMS for Methamphetamine Use Disorder". This is a pilot study to test the feasibility of a recruitment strategy and study protocol to examine the effects of a dual target transcranial magnetic stimulation treatment in methamphetamine use disorder. The study will test intermittent theta burst stimulation (TBS) targeting the dorsolateral pr...
What is the current status of trial NCT04449055?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2020-10-06. Estimated completion is 2022-03-31.
What conditions does trial NCT04449055 study?
This clinical trial studies the following conditions: Methamphetamine-dependence, Stimulant Dependence, Addiction, Drug.
What interventions are being tested in trial NCT04449055?
The interventions under investigation include: Transcranial Magnetic Stimulation--DPFC first, MPFC second (DEVICE), Transcranial Magnetic Stimulation--MPFC first, DPFC second (DEVICE).
Who is sponsoring clinical trial NCT04449055?
This trial is sponsored by Ryan M. Carnahan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04449055 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04449055's enrollment target sits among peer trials
19 16th of 18 higher than 3 of 18 other Methamphetamine-dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine-dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
MHealth Incentivized Adherence Plus Patient Navigation
ACTIVE NOT RECRUITING · NA
-
The Human Stress Response in a Simulated ED Setting
ACTIVE NOT RECRUITING · NA
-
Inflammation in Methamphetamine and STIs (IMSTI)
ACTIVE NOT RECRUITING · NA
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI